{"id":294929,"date":"2024-07-11T00:00:00","date_gmt":"2024-07-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0007-2024-biopharma-schizophrenia-unmet-need-unmet-need-cognitive-impairment-associated-with\/"},"modified":"2026-03-31T10:29:18","modified_gmt":"2026-03-31T10:29:18","slug":"unnecg0007-2024-biopharma-schizophrenia-unmet-need-unmet-need-cognitive-impairment-associated-with-schizophrenia-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0007-2024-biopharma-schizophrenia-unmet-need-unmet-need-cognitive-impairment-associated-with-schizophrenia-us-eu\/","title":{"rendered":"Schizophrenia &#8211; Unmet Need &#8211; Unmet Need &#8211; Cognitive Impairment Associated with Schizophrenia (US\/EU)"},"content":{"rendered":"<p><abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr> (e.g., impaired attention \/ vigilance, memory, and\/or executive function) negatively impacts patients\u2019 daily activities, occupational and social functioning, and adherence to antipsychotic treatment. Although the schizophrenia drug market is crowded, no drugs are approved specifically to treat <abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr>. Psychiatrists may prescribe either an adjunctive drug treatment (e.g., cognition-enhancing agent) or a nonpharmacological therapy (e.g., cognitive remediation) or both over a baseline antipsychotic regimen (for positive symptoms of schizophrenia); however, no therapy has demonstrated consistent efficacy in improving cognition in schizophrenia. Although the late-phase pipeline for <abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr> is sparse, Boehringer Ingelheim\u2019s iclepertin has had promising Phase 2 results and has received <abbr title=\"Food and Drug Administration\">FDA<\/abbr> breakthrough therapy designation for <abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr>. Great unmet need and commercial opportunity exist for an efficacious and safe therapy in this underserved schizophrenia segment.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which clinical \/ nonclinical attributes for a therapy influence psychiatrists\u2019 treatment decisions in <abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr>?<\/li>\n<li>How do psychiatrists rate the performance of key current therapies on treatment drivers and goals for <abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr>?<\/li>\n<li>What is the relative level of need for improved treatment options in <abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr> and related diseases, and in other schizophrenia symptom domains? What are the prevailing areas of unmet need in <abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr>?<\/li>\n<li>How do psychiatrists\u2019 preference and likelihood to prescribe vary across the set of user-defined Target Product Profiles in <abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/p>\n<p><strong>Key feature<\/strong><\/p>\n<p>The Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n<p><strong>Markets covered: <\/strong>United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30 European psychiatrists fielded in May 2024<\/p>\n<p><strong>Key companies: <\/strong>Otsuka Pharmaceutical, Lundbeck, Boehringer Ingelheim, Johnson &#038; Johnson Innovative Medicine, Novartis, AbbVie, Eisai, Teva<\/p>\n<p><strong>Key drugs: <\/strong>Aripiprazole, risperidone, rivastigmine, memantine, donepezil, modafinil<\/p>\n","protected":false},"template":"","class_list":["post-294929","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psychiatry","biopharma-therapy-areas-schizophrenia","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294929\/revisions"}],"predecessor-version":[{"id":575940,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294929\/revisions\/575940"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=294929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}